Medicare drug coverage

Rezurock in Pennsylvania: 2027 Part D coverage

169 of 324 Part D plans offered in Pennsylvania (52%) list Rezurock on their 2027 formulary, up 10 points from 2026. 100% of those require prior authorization, step therapy, or a quantity limit.

License. US government work, Public Domain Mark 1.0.

Pennsylvania compared with the nation

100% of the 324 Part D plans offered in Pennsylvania leave Rezurock off the 2027 formulary or restrict it, against 98% nationally (2 points higher). Pennsylvania ranks 23 of 51 from most to least restrictive. A plan offered in several states counts in each.

Rezurock in every state and by parent organization

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

2027 compared with 2026

Rezurock Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file319324+5
Plans that list it135 (42%)169 (52%)+10 points
Prior authorization (of plans that list it)135 (100%)169 (100%)no change
Step therapy (of plans that list it)0 (0%)0 (0%)no change
Quantity limit (of plans that list it)135 (100%)169 (100%)no change
Any of the three (of plans that list it)135 (100%)169 (100%)no change
Not listed or restricted (of all plans)319 (100%)324 (100%)no change

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Formulary tier

Rezurock formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 19 (7%)5 (3%)
Tier 5126 (93%)164 (97%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

Rezurock: plans in both 2026 and 2027
Plan by planPlans
Same plan id in both years268
Listed it in 2026, not in 20275 (2%)
Listed it in 2027, not in 202625 (9%)
Moved it to a higher tier4 (1%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit0 (0%)
Added at least one of the three0 (0%)
Removed at least one of the three0 (0%)
Plan ids new in 202756
2026 plan ids not in the 2027 file51

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Run it in Rivvi

Which 2027 plans near you dropped or restricted Rezurock?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan, before open enrollment.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Rezurock in other states

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.